MiraDX, Inc.

MiraDx is a biotechnology and health care startup based in the United States, founded in 2008. The company is dedicated to using unique microRNA-based biomarkers to personalize cancer treatment, as reflected in their slogan "Using unique microRNA-based biomarkers to personalize cancer treatment." Founded by Joanne Weidhaas, M.D., Ph.D. and Frank Slack, Ph.D., MiraDx's cutting-edge genetic research has unveiled a new class of genetic biomarkers based on microRNA biology. The company's mission is to apply these novel biomarkers to improve personalized cancer treatment. MiraDx has been applying these biomarkers to better direct cancer treatments, including radiation, chemotherapy, and newly developing immune therapies. Additionally, the company has been able to apply their biomarkers to address the daunting problem of toxicity from treatment, which no other set of biomarkers has been able to do. Their innovative approach has attracted significant attention, leading to a $4.00M Series A investment at 01 July 2010 from Connecticut Innovations. Through worldwide collaborations, MiraDx has advanced this class of biomarkers to the forefront of personalized therapy and has numerous collaborations across both academic and industry. In addition to their commercial efforts, MiraDx also fosters research and education through their non-profit organization, MiraKind, providing a holistic approach to addressing cancer treatment. The company's innovative approach and strong industry collaborations position them as a compelling player in the field of personalized cancer treatment. For further information, interested parties can visit their website at MiraDX.com and the sister non-profit MiraKind.org.